Emergence: creating better ADCs for Nectin-4

German start-up Emergence is launching with a large series A from U.S. and European investors to develop an ADC platform that aims to generate compounds with better therapeutic indexes than competitors’ programs, which could enable the start-up to compete on either efficacy or safety, or to go into a broader set of indications.

On Dec. 7, Emergence Therapeutics AG raised €87 million ($98.2 million) in a series A round led by Pontifax Venture Capital. ...